Overview
- 5 inspections across 5 sites are on record.
- 14 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2024-06-19.
At a glance
Inspections
5
Sites
5
Observations
14
Career since
May 2018
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| NerPharMa S.r.l. | 19 Jun 2024 | Human Drugs | On file |
| Lilly del Caribe, Inc | 16 Feb 2024 | Human Drugs | On file |
| Cenexi - Laboratoires Thissen Sa | 24 Jan 2020 | Human Drugs | View 483 → |
| Future Pak LLC | 12 Dec 2019 | Human Drugs | View 483 → |
| Recipharm Pharmaservices Private Limited | 11 May 2018 | Human Drugs | On file |
Sites inspected
NerPharMa S.r.l.Nerviano, Italy1 insp.
Lilly del Caribe, IncCarolina, United States1 insp.
Cenexi - Laboratoires Thissen SaBraine-l'Alleud, Belgium1 insp.
Future Pak LLCWixom, United States1 insp.
Recipharm Pharmaservices Private LimitedBengaluru, India1 insp.
Co-investigators
Investigators who share inspections with this person.
Yifan Wang1 shared
Marian E Ramirez1 shared
Ruo H Xu1 shared
Jose E Melendez1 shared
Jeffrey P Raimondi1 shared
Nina Ni1 shared
Andrew J Barrowcliff1 shared
Sarah E Rhoades1 shared
Emilie Kahn1 shared
Lata C Mathew1 shared
Full investigator report
Get the verbatim findings behind Daniel L Obrzut's 14 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site